Log in to your Inderes Free account to see all free content on this page.
Bavarian Nordic
148.85 DKK +3.26%HC Andersen Capital receives payment from Bavarian Nordic for a DigitalIR/Corporate Visibility agreement. See disclaimer.
27 investors are following this company
Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Revenue
7.06B
EBIT %
21.28 %
P/E
7.75
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
BAVA
Daily low / high price
144.75 / 149
DKK
Market cap
11.62B DKK
Turnover
43.05M DKK
Volume
292K
Latest videos
Financial calendar
Interim report
08.05.2024
Interim report
22.08.2024
Interim report
15.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
ATP Group | 10.1 % | 10.1 % |
Invesco | 5.0 % | 5.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio